First Time Loading...

PureTech Health PLC
LSE:PRTC

Watchlist Manager
PureTech Health PLC Logo
PureTech Health PLC
LSE:PRTC
Watchlist
Price: 219 GBX 2.34%
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

PRTC Price Targets Summary
PureTech Health PLC

Wall Street analysts forecast PRTC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRTC is 506.94 GBX with a low forecast of 373.7 GBX and a high forecast of 655.2 GBX.

PRTC Lowest Forecast
Wall Street Target
373.7 GBX
71% Upside
PRTC Average Forecast
Wall Street Target
506.94 GBX
131% Upside
PRTC Highest Forecast
Wall Street Target
655.2 GBX
199% Upside
Lowest
Price Target
373.7 GBX
71% Upside
Average
Price Target
506.94 GBX
131% Upside
Highest
Price Target
655.2 GBX
199% Upside
PureTech Health PLC Competitors:
Price Targets
EXEL
Exelixis Inc
24% Upside
300676
BGI Genomics Co Ltd
141% Upside
DYAI
Dyadic International Inc
435% Upside
KURN
Kuros Biosciences AG
204% Upside
EXEL
Exelixis Inc
24% Upside
300676
BGI Genomics Co Ltd
141% Upside
DYAI
Dyadic International Inc
435% Upside
KURN
Kuros Biosciences AG
204% Upside
ALKS
Alkermes Plc
49% Upside
B
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
76% Upside
VRTX
Vertex Pharmaceuticals Inc
18% Upside
PSTX
Poseida Therapeutics Inc
398% Upside

Revenue
Forecast

Revenue Estimate
PureTech Health PLC

For the last 8 years the compound annual growth rate for PureTech Health PLC's revenue is 28%. The projected CAGR for the next 4 years is 16%.

28%
Past Growth
16%
Estimated Growth
Estimates Accuracy
32%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
PureTech Health PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
PureTech Health PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
PRTC intrinsic value, competitors valuation, and company profile.
DCF Valuation
PRTC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PRTC stock valuation using valuation multiples.
Wall Street Estimates
PRTC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PRTC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PRTC's stock price target?
Price Target
506.94 GBX

According to Wall Street analysts, the average 1-year price target for PRTC is 506.94 GBX with a low forecast of 373.7 GBX and a high forecast of 655.2 GBX.

What is PureTech Health PLC's Revenue forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for PureTech Health PLC's revenue is 28%. The projected CAGR for the next 4 years is 16%.

ALPHA SPREAD
Join more than 134,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.